The tumor microenvironment has recently been shown to play decisive roles in chemotherapeutic response. In this issue of Cell, Yu et al. add to these findings by identifying the bacterium Fusobacterium nucleatum as a previously unrecognized chemoresistance mediator in colorectal cancer, thereby establishing the microbiota as a potential therapeutic target.
The recurrence of chemoresistant disease following therapy remains an intractable problem in oncology clinical care and represents a major impediment to reducing the morbidity and mortality attributable to malignant tumors. To address this issue, investigators have traditionally focused on elucidating the cell-intrinsic mechanisms and mutations that render tumors refractory to both classical chemotherapeutics and, more recently, to targeted therapies. However, cancers resident in organs throughout the body do not develop in isolation. Instead, tumor cells arise in the context of non-malignant cellular and non-cellular components of a tissue, defined as the tumor microenvironement (TME). While the importance of cell-extrinsic factors in cancer initiation and progression, including contributions from the TME, is well established, our understanding of the TME's influence on therapeutic outcome is in its infancy. Current studies have begun to address this question and have uncovered novel roles for the TME in modulating therapeutic efficacy. In the case of chemoresistance, the TME has now been shown to directly promote treatment failure by a diverse set of mechanisms, some of which are highlighted in Figures 1A-1C (Klemm and Joyce, 2015) . These limited examples suggest that specific mechanisms of drug resistance may vary significantly between cancers. However, the concept that neoplastic cells can co-opt preexisting or treatment-induced signaling networks to survive therapy has emerged as a clear, unifying component of treatment failure.
Tumors that arise at epithelial barrier surfaces of the body have the additional feature of harboring an extensive microbiota in the TME, and the importance of these microbes in human health and disease is now widely appreciated. Mounting evidence in colorectal cancer (CRC), for instance, has linked the microbiota resident in the TME to cancer initiation and progression. For instance, a subset of bacterial toxins have been shown to directly induce DNA damage responses and genomic instability in mammalian host cells, while other microbial proteins, including certain virulence factors, can engage host pathways that are important in carcinogenesis and inflammation (Garrett 2015) . Recently, the bacterium Fusobacterium nucleatum (Fn) has garnered considerable attention as a potential cancer-promoting microbe. Early observational studies demonstrated that Fn is enriched in human CRCs versus normal adjacent tissue, that increasing amounts of Fn track with tumor stage, and that increased Fn abundance is associated with advanced disease in CRC patients (Kostic et al., 2012; Castellarin et al., 2012) . Experimental studies later showed that this microbe can directly increase Wnt/b-catenin signaling when its adhesin FadA binds to E-cadherin on tumor cells, promoting inflammation and tumor cell growth pathways only in transformed cells (Rubinstein et al., 2013) . This raised the possibility that early cancer-initiating mutations precede the enrichment of Fn in diseased tissue. Experiments in adematous polyposis coli (Apc) min/+ mice and in mouse models of colitis, a type of inflammatory bowel disease and a known risk factor for CRC development, lent additional support this idea since exposure to Fn accelerated disease only in mice bearing pre-existing, CRC-promoting mutations (Apc min/+ mice) (Kostic et al., 2013) .
This study, along with a more recent report, also demonstrated that this bacterium can inhibit T-cell-and natural killercell-mediated immune responses against CRCs through its Fap2 lectin (Gur et al., 2015) . Together, these data implicate Fn in CRC susceptibility and progression, suggesting that it can directly accelerate carcinogenesis once mutations have occurred and, further, that it can promote tumor survival by inhibiting antitumor immunity. However, a role for this bacterium in chemotherapeutic response had not been previously reported. In this issue of Cell, Yu and colleagues address this question and report that Fn directly promotes CRC chemoresistance to oxaliplatin and 5-fluorouracil (5-FU) through a TLR4/MYD88-dependent-mechanism ( Figure 1D ) (Yu et al., 2017) . Using large cohorts of CRC patients, Yu et al. begin by establishing that high levels of Fn are associated with and predictive for CRC aggressiveness, poor outcome, and recurrence after therapy in patients, confirming and expanding the previous observational studies linking this microbe to CRC. These data raised the question of whether increased Fn abundance plays a causal role in CRC recurrence or is simply a consequence of it. The authors used a combination of RNA-seq experiments and functional assays to demonstrate that Fn induced activation of the autophagy pathway in CRC cells. By inhibiting apoptosis pathways in favor of autophagy, Fn also induced resistance to oxaliplatin and 5-FU, two drugs commonly used in CRC treatment paradigms. Experiments using reporter plasmids containing the promoter regions of ULK1 and ATG7 demonstrated that Fn likely does not promote upregulation of autophagy via transcriptional mechanisms. Instead, investigations into the miRNA transcriptome revealed two miRNAs (miRNA-18a* and miRNA-4802) that act on ULK1 and ATG7 mRNAs and were downregulated by Fn in a TLR4/MYD88-dependent manner. Taken as a whole, the data support a model in which Fn rewires tumor cells to survive chemotherapy.
The idea that the antitumor effects of chemotherapeutic agents could be (C) In the bone marrow, leukemic cells can interact with intrinsic features of the TME, such as the extracellular matrix (ECM), via integrin receptors. This interaction has been shown to induce a cell-adhesion-mediated drug resistance (CAM-DR) phenotype, including the upregulation of multiple drug resistance (MDR) pumps and increased signaling through pro-survival pathways. OB, osteoblast; OC, osteoclast. (D) Yu et al. present a novel mechanism by which the TME promotes chemoresistance in this issue of Cell. The TLR4 and MYD88 signaling pathway is essential for Fusobacterium nucleatum (Fn) infection. CRC cells resident in the gut can co-opt this colonization property by interacting with Fn. TLR4/MYD88 activation by this microbe downregulates miRNA-18a* and miRNA-4082, inducing a switch from apoptosis to autophagy in CRC cells and allowing them to survive therapy.
inhibited by specific members of the microbiota is surprising, given that previous animal studies have demonstrated a beneficial role of the intestinal microbiota in promoting cancer chemotherapy (Alexander et al., 2017) . For example, a recent study demonstrated a dramatic decrease in the antitumor effect of oxaliplatin in germ-free or antibiotictreated animals (Iida et al., 2013) . Here, the microbiota were shown to prime tumor-infiltrating myeloid cells for cytotoxic reactive oxygen species (ROS) production, partially through TLR4 signaling and in a MYD88-dependent manner. Whether similar results would be seen in human cancer patients, even those treated with antibiotics during their treatment course, remains unclear. Similarly, the study by Yu and colleagues was completed in tumor xenografts that developed outside the normal CRC TME and were directly injected with Fn to elicit a resistance phenotype. As such, the relevance of either study to human cancer, particularly in the context of antibiotic treatment, requires further evaluation. In any case, the relationship between the microbiota and therapeutic outcome is likely complicated, multi-factorial, and context specific.
The finding that Fn can activate autophagy in CRC cells during chemotherapy treatment has important implications in CRC treatment, as the inhibition of autophagy and/or elimination of Fn could potentiate the effects of current front-line therapies. However, these data also raise a number of important questions. For example, we do not know whether Fn's ability to promote chemoresistance by engaging autophagy is specific to this bacterial species or whether other Gram-negative bacterial species associated with CRC recurrence in Yu et al.'s study (Parvimonas, Peptostreptococcus, or Prevotella) or in previous reports (Bacteroides fragilis) can induce the same effect (Garrett 2015) . Thus, it is unclear whether targeting specific bacterial species or inhibiting autophagy more generally will be most beneficial to CRC treatment. Another important challenge is translation of these findings into the clinic. To date, no strategies to selectively alter the composition of the human microbiota exist. However, the recent success in inhibiting bacterial b-glucuronidases to attenuate Irinotecan toxicity provides some hope that targeting the microbiome could soon be a viable strategy (Alexander et al., 2017) . Further insights into how tumor cells co-opt intrinsic or druginduced features of the TME to survive therapy may allow us to generate new treatment strategies that can target critical TME factors that promote resistance. Ultimately, these TME-targeted therapeutics should potentiate the effects of preexisting chemotherapies, increase their efficacy, and improve patient outcomes.
